Insmed Incorporated (NASDAQ:INSM) Shares Sold by Essex Investment Management Co. LLC

Essex Investment Management Co. LLC lessened its position in Insmed Incorporated (NASDAQ:INSM - Free Report) by 12.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 67,330 shares of the biopharmaceutical company's stock after selling 9,863 shares during the quarter. Essex Investment Management Co. LLC's holdings in Insmed were worth $4,648,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. CIBC Asset Management Inc grew its stake in shares of Insmed by 3.5% in the third quarter. CIBC Asset Management Inc now owns 4,438 shares of the biopharmaceutical company's stock worth $324,000 after acquiring an additional 149 shares in the last quarter. Abel Hall LLC grew its stake in shares of Insmed by 4.7% during the fourth quarter. Abel Hall LLC now owns 3,333 shares of the biopharmaceutical company's stock worth $230,000 after purchasing an additional 151 shares in the last quarter. Commerce Bank increased its holdings in Insmed by 2.4% in the third quarter. Commerce Bank now owns 6,833 shares of the biopharmaceutical company's stock valued at $499,000 after buying an additional 163 shares during the last quarter. Steward Partners Investment Advisory LLC raised its stake in Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 163 shares in the last quarter. Finally, M&T Bank Corp lifted its holdings in Insmed by 5.6% during the 4th quarter. M&T Bank Corp now owns 3,146 shares of the biopharmaceutical company's stock worth $217,000 after buying an additional 166 shares during the last quarter.

Remove Ads

Analyst Ratings Changes

A number of research firms have recently commented on INSM. Guggenheim reiterated a "buy" rating and issued a $101.00 price objective on shares of Insmed in a report on Tuesday, February 25th. Cantor Fitzgerald reissued an "overweight" rating on shares of Insmed in a report on Wednesday, February 19th. JPMorgan Chase & Co. boosted their price objective on shares of Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a research report on Friday, February 7th. Wells Fargo & Company increased their target price on shares of Insmed from $85.00 to $107.00 and gave the company an "overweight" rating in a research report on Wednesday, February 19th. Finally, Stifel Nicolaus cut their price target on shares of Insmed from $97.00 to $96.00 and set a "buy" rating on the stock in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to MarketBeat.com, Insmed presently has a consensus rating of "Moderate Buy" and a consensus target price of $93.33.

Insider Activity at Insmed

In other news, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the firm's stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $80.00, for a total value of $7,291,200.00. Following the completion of the sale, the insider now directly owns 97,083 shares of the company's stock, valued at $7,766,640. This trade represents a 48.42 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Martina M.D. Flammer sold 3,344 shares of the company's stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total value of $220,403.04. Following the transaction, the insider now directly owns 102,766 shares in the company, valued at $6,773,307.06. This represents a 3.15 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 550,957 shares of company stock worth $42,859,028 in the last three months. Insiders own 4.60% of the company's stock.

Insmed Stock Performance

INSM stock traded up $1.03 during trading on Thursday, hitting $75.07. The company had a trading volume of 1,186,555 shares, compared to its average volume of 1,955,024. The firm has a 50-day moving average price of $75.93 and a 200-day moving average price of $73.71. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The firm has a market cap of $13.59 billion, a PE ratio of -13.43 and a beta of 1.28. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $84.91.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company had revenue of $104.44 million during the quarter, compared to analysts' expectations of $102.31 million. On average, analysts expect that Insmed Incorporated will post -4.56 earnings per share for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.